Liquid biopsy for early diagnosis of non-small cell lung carcinoma: recent research and detection technologies

Chang, Lu; Li, Jinming; Zhang, Rui

doi:10.1016/j.bbcan.2022.188729

Cited by 22 publications

(13 citation statements)

References 174 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PCR remains the most widely used method among these. PCR-based techniques include standard quantitative PCR (qPCR), digital PCR (dPCR) and droplet digital PCR (ddPCR), allele-specific PCR, quantitative methylationspecific PCR, BEAMing (beads, emulsions, amplification, and magnetism) [111][112][113], ARMS [114], and co-amplification at lower denaturation temperature-PCR [115]. The sensitivity of PCR-based assays has increased dramatically over the past decade.…”

Section: Detection Methods Of Cfdna/ctdnamentioning

confidence: 99%

Clinical application and detection techniques of liquid biopsy in gastric cancer

Zhou

et al. 2023

Mol Cancer

View full text Add to dashboard Cite

Gastric cancer (GC) is one of the most common tumors worldwide and the leading cause of tumor-related mortality. Endoscopy and serological tumor marker testing are currently the main methods of GC screening, and treatment relies on surgical resection or chemotherapy. However, traditional examination and treatment methods are more harmful to patients and less sensitive and accurate. A minimally invasive method to respond to GC early screening, prognosis monitoring, treatment efficacy, and drug resistance situations is urgently needed. As a result, liquid biopsy techniques have received much attention in the clinical application of GC. The non-invasive liquid biopsy technique requires fewer samples, is reproducible, and can guide individualized patient treatment by monitoring patients' molecular-level changes in real-time. In this review, we introduced the clinical applications of circulating tumor cells, circulating free DNA, circulating tumor DNA, non-coding RNAs, exosomes, and proteins, which are the primary markers in liquid biopsy technology in GC. We also discuss the current limitations and future trends of liquid biopsy technology as applied to early clinical biopsy technology.

show abstract

Section: Detection Methods Of Cfdna/ctdnamentioning

confidence: 99%

Clinical application and detection techniques of liquid biopsy in gastric cancer

Zhou

et al. 2023

Mol Cancer

View full text Add to dashboard Cite

show abstract

“…In NSCLC, ctDNA levels are closely associated with tumor volume, distinguishing between treatment-related imaging transformations and residual disease, allowing for earlier response assessment and personalized cancer treatment (135). There are also many other detection techniques such as polymerase chain reaction-based, microfluidic methods, chipbased, next-generation sequencing-based, and fluorescence in situ hybridization-based (136). However, the specificity of liquid biopsy results poses some challenges.…”

Section: Opportunities and Challenges Of Liquid Biopsy Technology In ...mentioning

confidence: 99%

Liquid Biopsy in Pre-Metastatic Niche: From Molecular Mechanism to Clinical Application

et al. 2022

View full text Add to dashboard Cite

Metastatic dissemination represents a hallmark of cancer that is responsible for the high mortality rate. Recently, emerging evidence demonstrates a time-series event—pre-metastatic niche (PMN) has a profound impact on cancer metastasis. Exosomes, cell-free DNA (cfDNA), circulating tumor cells (CTC), and tumor microenvironment components, as critical components in PMN establishment, could be monitored by liquid biopsy. Intensive studies based on the molecular profile of liquid biopsy have made it a viable alternative to tissue biopsy. Meanwhile, the complex molecular mechanism and intercellular interaction are great challenges for applying liquid biopsy in clinical practice. This article reviews the cellular and molecular components involved in the establishment of the PMN and the promotion of metastasis, as well as the mechanisms of their interactions. Better knowledge of the characteristics of the PMN may facilitate the application of liquid biopsy for clinical diagnosis, prognosis, and treatment.

show abstract

“…Histopathological examination is the gold standard for the diagnosis of NSCLC. However, due to the invasive nature of histopathological examination, detecting lung cancer tumour markers is an important way to achieve early diagnosis of lung cancer, and biomarker testing using body uids such as blood, urine, and saliva has become an important method for cancer diagnosis 4,5 . In recent years, markers such as DNA methylation 6,7 , circulating tumour DNA 8,9 , circulating tumour cells 10,11 , and microRNAs 12 have provided certain molecular biological information at an early stage to assist in the screening of earlystage lung cancer.…”

Section: Introductionmentioning

confidence: 99%

A high-performance metabolomic diagnostic panel for early-stage non-small cell lung cancer detection based on UPLC‒MS/MS

Wan,

Liu,

Liang

et al. 2024

Preprint

View full text Add to dashboard Cite

Lung cancer is the most common cancer in the world and has a consistently high mortality rate, with the majority of patients being diagnosed at an advanced stage. This study aimed to identify potential biomarkers through metabolomics to provide clues for the diagnosis and treatment of early-stage non-small cell lung cancer (NSCLC). We enrolled two prospective cohorts with a total of 180 patients (115 patients with I-II a NSCLC and 65 healthy controls) and tested serum samples for tumour markers, cytokines, and 306 metabolites by ultrahigh-performance liquid chromatography coupled with tandem mass spectrometry (UPLC‒MS/MS). In both the discovery and validation cohorts, there were 57 differentially abundant metabolites in the serum between patients with early-stage NSCLC and healthy controls, which were concentrated in the fatty acid metabolic pathway and amino acid metabolic pathway. Finally, three metabolites with significant differences were screened as isoleucine, 5Z-dodecenoic acid and 9E-tetradecenoic acid. The AUC of centralized combined diagnosis reached 0.95. This study provides new evidence that abnormalities in valine, leucine, and isoleucine metabolism and dysregulation of fatty acid synthesis may play important roles in the development of NSCLC.

show abstract

Liquid biopsy for early diagnosis of non-small cell lung carcinoma: recent research and detection technologies

Cited by 22 publications

References 174 publications

Clinical application and detection techniques of liquid biopsy in gastric cancer

Clinical application and detection techniques of liquid biopsy in gastric cancer

Liquid Biopsy in Pre-Metastatic Niche: From Molecular Mechanism to Clinical Application

A high-performance metabolomic diagnostic panel for early-stage non-small cell lung cancer detection based on UPLC‒MS/MS

Contact Info

Product

Resources

About